Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

675 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.
Fung HC, Cohen S, Rodriguez R, Smith D, Krishnan A, Somlo G, Sahebi F, Senitzer D, O'Donnell MR, Stein A, Snyder DS, Spielberger R, Bhatia R, Falk P, Molina A, Nademanee A, Parker P, Kogut N, Popplewell L, Vora N, Margolin K, Forman SJ. Fung HC, et al. Among authors: forman sj. Biol Blood Marrow Transplant. 2003 Oct;9(10):649-56. doi: 10.1016/s1083-8791(03)00241-6. Biol Blood Marrow Transplant. 2003. PMID: 14569561 Free article. Clinical Trial.
Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies.
Somlo G, Chow W, Hamasaki V, Leong L, Margolin K, Morgan R Jr, Sniecinski I, Frankel P, Reardon D, Longmate E, Raschko J, Shibata S, O'Donnell M, Smith E, Tetef M, Forman S, Yen Y, Molina A, Doroshow H. Somlo G, et al. Biol Blood Marrow Transplant. 2001;7(5):284-93. doi: 10.1053/bbmt.2001.v7.pm11400951. Biol Blood Marrow Transplant. 2001. PMID: 11400951 Free article. Clinical Trial.
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
Morgan RJ, Doroshow JH, Leong L, Schriber J, Shibata S, Forman S, Hamasaki V, Margolin K, Somlo G, Alvarnas J, McNamara M, Longmate J, Raschko J, Chow W, Vasilev S, McGonigle K, Yen Y. Morgan RJ, et al. Bone Marrow Transplant. 2001 Nov;28(9):859-63. doi: 10.1038/sj.bmt.1703243. Bone Marrow Transplant. 2001. PMID: 11781646 Clinical Trial.
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.
VanderWalde A, Ye W, Frankel P, Asuncion D, Leong L, Luu T, Morgan R, Twardowski P, Koczywas M, Pezner R, Paz IB, Margolin K, Wong J, Doroshow JH, Forman S, Shibata S, Somlo G. VanderWalde A, et al. Biol Blood Marrow Transplant. 2012 Aug;18(8):1273-80. doi: 10.1016/j.bbmt.2012.01.021. Epub 2012 Feb 2. Biol Blood Marrow Transplant. 2012. PMID: 22306735 Free PMC article. Clinical Trial.
Thalidomide as salvage therapy for chronic graft-versus-host disease.
Parker PM, Chao N, Nademanee A, O'Donnell MR, Schmidt GM, Snyder DS, Stein AS, Smith EP, Molina A, Stepan DE, Kashyap A, Planas I, Spielberger R, Somlo G, Margolin K, Zwingenberger K, Wilsman K, Negrin RS, Long GD, Niland JC, Blume KG, Forman SJ. Parker PM, et al. Among authors: forman sj. Blood. 1995 Nov 1;86(9):3604-9. Blood. 1995. PMID: 7579470 Free article. Clinical Trial.
In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
Stein AS, O'Donnell MR, Chai A, Schmidt GM, Nademanee A, Parker PM, Smith EP, Snyder DS, Molina A, Stepan DE, Spielberger R, Somlo G, Margolin KA, Vora N, Lipsett J, Lee J, Niland J, Forman SJ. Stein AS, et al. Among authors: forman sj. J Clin Oncol. 1996 Aug;14(8):2206-16. doi: 10.1200/JCO.1996.14.8.2206. J Clin Oncol. 1996. PMID: 8708709 Clinical Trial.
Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.
Chao NJ, Parker PM, Niland JC, Wong RM, Dagis A, Long GD, Nademanee AP, Negrin RS, Snyder DS, Hu WW, Gould KA, Tierney DK, Zwingenberger K, Forman SJ, Blume KG. Chao NJ, et al. Among authors: forman sj. Biol Blood Marrow Transplant. 1996 May;2(2):86-92. Biol Blood Marrow Transplant. 1996. PMID: 9118303 Clinical Trial.
Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group.
Nademanee A, Molina A, O'Donnell MR, Dagis A, Snyder DS, Parker P, Stein A, Smith E, Planás I, Kashyap A, Spielberger R, Fung H, Wong KK, Somlo G, Margolin K, Chow W, Sniecinski I, Vora N, Blume KG, Niland J, Forman SJ. Nademanee A, et al. Among authors: forman sj. Blood. 1997 Nov 15;90(10):3844-52. Blood. 1997. PMID: 9354650 Free article. Clinical Trial.
Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SJ, Blume KG. Long GD, et al. Among authors: forman sj. Biol Blood Marrow Transplant. 1997 Dec;3(6):324-30. Biol Blood Marrow Transplant. 1997. PMID: 9502300 Clinical Trial.
675 results